SCHEMBL3339985

SCHEMBL3339985

O=Cc1ccc(-c2noc(-c3cn4cc(C(F)(F)F)cc(Br)c4n3)n2)c(Cl)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.39
NFKB1 P19838 4/20 0.39
RAB9A P51151 4/20 0.39
NFKB2 Q00653 4/20 0.39
RELA Q04206 4/20 0.39
SMN1; SMN2 Q16637 4/20 0.39
MAPT P10636 2/20 0.39
LMNA P02545 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
RECQL P46063 1/20 0.39
PKM P14618 1/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
CNR2 P34972 3/20 0.34
HDAC4 P56524 2/20 0.34
HDAC6 Q9UBN7 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13330845 0.94 HSD11B1 (0.34) NPC1NFKB1RAB9ANFKB2RELA
SCHEMBL3343142 0.92 NPC1 (0.48) NPC1NFKB1RAB9ANFKB2RELA
SCHEMBL3345945 0.87 NPC1 (0.48) NPC1NFKB1RAB9ANFKB2RELA
SCHEMBL3339960 0.84 NPC1 (0.48) NPC1NFKB1RAB9ANFKB2RELA
SCHEMBL3343764 0.83 NPC1 (0.39) NPC1NFKB1RAB9ANFKB2RELA
SCHEMBL3340987 0.81 NPC1 (0.39) NPC1NFKB1RAB9ANFKB2RELA
SCHEMBL3339957 0.80 RARA (0.39) NPC1NFKB1RAB9ANFKB2RELA
SCHEMBL3340394 0.80 SMN1; SMN2 (0.55) NPC1NFKB1RAB9ANFKB2RELA
SCHEMBL3339266 0.79 CNR2 (0.38) NPC1NFKB1RAB9ANFKB2RELA
SCHEMBL3343797 0.79 NPC1 (0.46) NPC1NFKB1RAB9ANFKB2RELA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100160369-A1 S1P1 Agonists and Methods of Making And Using EXELIXIS, INC. (US) 2010-06-24 US disclosed
US-20100160369-A1 S1P1 Agonists and Methods of Making And Using EXELIXIS, INC. (US) 2010-06-24 US disclosed
US-20100160369-A1 S1P1 Agonists and Methods of Making And Using EXELIXIS, INC. (US) 2010-06-24 US disclosed
WO-2010065760-A1 IMIDAZO [1,2A] PYRIDINE DERIVATIVES, THEIR USE AS S1P1 AGONISTS AND METHODS FOR THEIR PRODUCTION EXELIXIS, INC. (US) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160369-A1 S1P1 Agonists and Methods of Making And Using S1PR1, S1PR5, S1PR3 NPC1 241/4885NFKB1 3452/4885RAB9A 2844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.